Pine Labs Limited (PINELABS)
As per the enclosed file.
AI summary
- Q1 FY27 revenue grew about 20% y-y, within guided 21-23.5% range
- Contribution margin impacted by higher distribution growth and upfront investments; expected to rise to 73-74% in H2FY27
- International business growing fast with new contracts; losses in new geographies expected to breakeven in 1-2 years
- Cloud and network costs increased by Rs 20-22 Cr; about half expected to recur
- Flow-based income and issuing side growing ~25% y-y; online and bill payments growing 50%+
- Offline POS UPI transactions now 70%+ with average ticket size Rs 1400+
- Sales force expanded by 500 to capture offline and online merchant opportunities
- EBITDA margin expected not to fall below last year's 23.5%; investments to bear fruit over next quarters
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 PINELABS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add PINELABS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Pine Labs Limited
Important.
The summary above is generated automatically from Pine Labs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.